These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32429775)

  • 1. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
    Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
    Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
    Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L
    Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK; Thukral SS; Gaind R
    Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
    Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croatia.
    Sardelić S; Bedenić B; Sijak D; Colinon C; Kalenić S
    Chemotherapy; 2010; 56(3):208-13. PubMed ID: 20551637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.